Superman Bacteria, Gene Therapy for Heart Failure + Next-Gen Organoids!

Hi ,

This week’s Digest showcases the profound intersections of biology and technology. Researchers have transformed E. coli into "Superman bacteria," dramatically improving sustainability in industrial microbiology, while a promising gene therapy targeting heart failure could redefine treatment paradigms. Advances in tumor organoid research are bringing personalized CAR T therapies closer to reality, and a new NSF-backed project is turning CO2 into cellulose, charting a sustainable path for textiles. With insights into AI-driven crop DNA innovation and the role of START domains in gene regulation, this issue delves into the science shaping our world—and our future. But first, meet a host of new speakers who will be presenting at SynBioBeta 2025!

Enjoy the rest of your week!

Meet the Latest Speakers for SynBioBeta 2025!

Don’t miss your chance to hear from the brightest minds in the industry. Secure your spot for SynBioBeta 2025 today!

Check Out Our Latest Sponsors and Exhibitors for SynBioBeta 2025!

“Superman Bacteria" and the Promise of a Greener Industrial Microbiology

A breakthrough in microbial engineering has transformed E. coli into “Superman bacteria,” cutting energy costs and boosting sustainability in industrial microbiology.

Heart Failure May Soon Be Reversible with New Gene Therapy

A novel therapy that replenishes cBIN1 protein in cardiac cells may hold the key to reversing heart failure’s relentless progression.

Rubi Secures $1 Million NSF Grant to Scale Carbon-to-Cellulose Technology

The company’s innovative cell-free biocatalysis technology aims to decarbonize textile production by creating CO2-derived cellulose as a sustainable alternative to wood pulp.